LC treatment ameliorated hepatic fat accumulation, limited ROS production, improved the fibrosis progression of NAFLD, significantly reduced the NF-kB protein content. This evidence concerns the gene NFKB1 and metabolic dysfunction-associated steatotic liver disease.